168 related articles for article (PubMed ID: 38359985)
21. APOBEC3A is a prominent cytidine deaminase in breast cancer.
Cortez LM; Brown AL; Dennis MA; Collins CD; Brown AJ; Mitchell D; Mertz TM; Roberts SA
PLoS Genet; 2019 Dec; 15(12):e1008545. PubMed ID: 31841499
[TBL] [Abstract][Full Text] [Related]
22. Distinct Mutagenic Activity of APOBEC3G Cytidine Deaminase Identified in Bladder Cancer.
Caswell D; Swanton C
Cancer Res; 2023 Feb; 83(4):487-488. PubMed ID: 36789568
[TBL] [Abstract][Full Text] [Related]
23. Prospectively defined patterns of APOBEC3A mutagenesis are prevalent in human cancers.
DeWeerd RA; Németh E; Póti Á; Petryk N; Chen CL; Hyrien O; Szüts D; Green AM
Cell Rep; 2022 Mar; 38(12):110555. PubMed ID: 35320711
[TBL] [Abstract][Full Text] [Related]
24. Association of a germline copy number polymorphism of APOBEC3A and APOBEC3B with burden of putative APOBEC-dependent mutations in breast cancer.
Nik-Zainal S; Wedge DC; Alexandrov LB; Petljak M; Butler AP; Bolli N; Davies HR; Knappskog S; Martin S; Papaemmanuil E; Ramakrishna M; Shlien A; Simonic I; Xue Y; Tyler-Smith C; Campbell PJ; Stratton MR
Nat Genet; 2014 May; 46(5):487-91. PubMed ID: 24728294
[TBL] [Abstract][Full Text] [Related]
25. Quantification of ongoing APOBEC3A activity in tumor cells by monitoring RNA editing at hotspots.
Jalili P; Bowen D; Langenbucher A; Park S; Aguirre K; Corcoran RB; Fleischman AG; Lawrence MS; Zou L; Buisson R
Nat Commun; 2020 Jun; 11(1):2971. PubMed ID: 32532990
[TBL] [Abstract][Full Text] [Related]
26. Degradation of the cancer genomic DNA deaminase APOBEC3B by SIV Vif.
Land AM; Wang J; Law EK; Aberle R; Kirmaier A; Krupp A; Johnson WE; Harris RS
Oncotarget; 2015 Nov; 6(37):39969-79. PubMed ID: 26544511
[TBL] [Abstract][Full Text] [Related]
27. A Conserved Mechanism of APOBEC3 Relocalization by Herpesviral Ribonucleotide Reductase Large Subunits.
Cheng AZ; Moraes SN; Attarian C; Yockteng-Melgar J; Jarvis MC; Biolatti M; Galitska G; Dell'Oste V; Frappier L; Bierle CJ; Rice SA; Harris RS
J Virol; 2019 Dec; 93(23):. PubMed ID: 31534038
[TBL] [Abstract][Full Text] [Related]
28. Structural Characterization of a Minimal Antibody against Human APOBEC3B.
Tang H; Demir Ö; Kurniawan F; Brown WL; Shi K; Moeller NH; Carpenter MA; Belica C; Orellana K; Du G; LeBeau AM; Amaro RE; Harris RS; Aihara H
Viruses; 2021 Apr; 13(4):. PubMed ID: 33921405
[TBL] [Abstract][Full Text] [Related]
29. Pan-cancer transcriptomic analysis dissects immune and proliferative functions of APOBEC3 cytidine deaminases.
Ng JCF; Quist J; Grigoriadis A; Malim MH; Fraternali F
Nucleic Acids Res; 2019 Feb; 47(3):1178-1194. PubMed ID: 30624727
[TBL] [Abstract][Full Text] [Related]
30. APOBEC3A damages the cellular genome during DNA replication.
Green AM; Landry S; Budagyan K; Avgousti DC; Shalhout S; Bhagwat AS; Weitzman MD
Cell Cycle; 2016; 15(7):998-1008. PubMed ID: 26918916
[TBL] [Abstract][Full Text] [Related]
31. Interaction with the CCT chaperonin complex limits APOBEC3A cytidine deaminase cytotoxicity.
Green AM; DeWeerd RA; O'Leary DR; Hansen AR; Hayer KE; Kulej K; Dineen AS; Szeto JH; Garcia BA; Weitzman MD
EMBO Rep; 2021 Sep; 22(9):e52145. PubMed ID: 34347354
[TBL] [Abstract][Full Text] [Related]
32. Biochemical analysis of hypermutation by the deoxycytidine deaminase APOBEC3A.
Love RP; Xu H; Chelico L
J Biol Chem; 2012 Aug; 287(36):30812-22. PubMed ID: 22822074
[TBL] [Abstract][Full Text] [Related]
33. APOBEC3A and APOBEC3B are potent inhibitors of LTR-retrotransposon function in human cells.
Bogerd HP; Wiegand HL; Doehle BP; Lueders KK; Cullen BR
Nucleic Acids Res; 2006; 34(1):89-95. PubMed ID: 16407327
[TBL] [Abstract][Full Text] [Related]
34. Distinguishing preferences of human APOBEC3A and APOBEC3B for cytosines in hairpin loops, and reflection of these preferences in APOBEC-signature cancer genome mutations.
Butt Y; Sakhtemani R; Mohamad-Ramshan R; Lawrence MS; Bhagwat AS
Nat Commun; 2024 Mar; 15(1):2369. PubMed ID: 38499553
[TBL] [Abstract][Full Text] [Related]
35. Impact of the APOBEC3A/B deletion polymorphism on risk of ovarian cancer.
Gansmo LB; Sofiyeva N; Bjørnslett M; Romundstad P; Hveem K; Vatten L; Dørum A; Lønning PE; Knappskog S
Sci Rep; 2021 Dec; 11(1):23463. PubMed ID: 34873230
[TBL] [Abstract][Full Text] [Related]
36. APOBEC3B: pathological consequences of an innate immune DNA mutator.
Burns MB; Leonard B; Harris RS
Biomed J; 2015; 38(2):102-10. PubMed ID: 25566802
[TBL] [Abstract][Full Text] [Related]
37. BE-FLARE: a fluorescent reporter of base editing activity reveals editing characteristics of APOBEC3A and APOBEC3B.
Coelho MA; Li S; Pane LS; Firth M; Ciotta G; Wrigley JD; Cuomo ME; Maresca M; Taylor BJM
BMC Biol; 2018 Dec; 16(1):150. PubMed ID: 30593278
[TBL] [Abstract][Full Text] [Related]
38. Transcriptional repression and apoptosis influence the effect of APOBEC3A/3B functional polymorphisms on biliary tract cancer risk.
Liu W; Ji H; Zhao J; Song J; Zheng S; Chen L; Li P; Tan X; Ding Y; Pu R; Yin J; Han X; Cao G
Int J Cancer; 2022 Jun; 150(11):1825-1837. PubMed ID: 35020946
[TBL] [Abstract][Full Text] [Related]
39. Analysis of APOBEC3A/3B germline deletion polymorphism in breast, cervical and oral cancers from South India and its impact on miRNA regulation.
Revathidevi S; Manikandan M; Rao AK; Vinothkumar V; Arunkumar G; Rajkumar KS; Ramani R; Rajaraman R; Ajay C; Munirajan AK
Tumour Biol; 2016 Sep; 37(9):11983-11990. PubMed ID: 27155849
[TBL] [Abstract][Full Text] [Related]
40. Clearing of Foreign Episomal DNA from Human Cells by CRISPRa-Mediated Activation of Cytidine Deaminases.
Brezgin S; Kostyusheva A; Ponomareva N; Volia V; Goptar I; Nikiforova A; Shilovskiy I; Smirnov V; Kostyushev D; Chulanov V
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32962129
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
